This free telephone/web education program was presented live on February 17, 2015. For questions regarding the content of this program, please contact an LLS Information Specialist at 800-955-4572 or infocenter@LLS.org. We encourage you to share this program with anyone who … Continued
FDA modified the indication for erlotinib (TARCEVA, Astellas Pharm Global Development Inc.) for treatment of non-small cell lung cancer (NSCLC) to limit use to patients whose tumors have specific epidermal growth factor receptor (EGFR) mutations. October 18, 2016.
For healthcare providers, the MACRA rule was released today. It urges you to understand and learn how this will affect you because it will. Patients should also see how this will affect you because similar to Affordable Care, it will.